(Q34504305)

2 August 2017

title

ESHAP is an active regimen for relapsing Hodgkin's disease (English)

1 reference

2 August 2017

J Aparicio

1

1 reference

2 August 2017

A Segura

2

1 reference

2 August 2017

S Garcerá

3

1 reference

2 August 2017

A Oltra

4

1 reference

2 August 2017

A Santaballa

5

1 reference

2 August 2017

A Yuste

6

1 reference

2 August 2017

M Pastor

7

1 reference

2 August 2017

publication date

1 May 1999

1 reference

2 August 2017

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

593-595

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

2 August 2017

1 reference

7 January 2021

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

7 January 2021

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

7 January 2021

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026454831340

7 January 2021

Identifiers

DOI

10.1023/A:1026454831340

1 reference

2 August 2017

1 reference